| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L02 - Endocrine Therapy | Estrogens and progestogens used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system.
| The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).
|
|
| L02A - Hormones and Related Agents | Antigrowth hormones like somatostatin and octreotide, which are also used in the treatment of neoplastic diseases, are classified in H01CB.
|
|
| L02AE - Gonadotropin Releasing Hormone Analogues | See also H01CA - Gonadotropin releasing hormones.
A combi-pack containing leuprorelin (L02AE02) injection and bicalutamide (L02BB03) tablets indicated for prostate cancer is classified in L02AE51.
| The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.
The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.
|
|
| L02AE02 - Leuprorelin | | Dose | Route of administration | Note |
|---|
| | i | | | | P | depot inj | | | P | |
|
|
